中国百日咳诊疗与预防指南(2024版)  

Guidelines for diagnosis and management and prevention of pertussis of China (2024 edition)

作　　者：中华医学会感染病学分会儿科感染学组 国家卫生健康委能力建设和继续教育儿科专委会感染组 中国临床实践指南联盟方法学专委会 国家儿童医学中心(上海) 国家传染病医学中心 曾玫 邵祝军[3] 张文宏 夏君 蔡洁皓 陈明亮[7] 冯天行 姚开虎 Pediatric Infection Group,Chinese Society of Infectious Diseases,Chinese Medical Association;Infection Group,Pediatric Expert Committee of National Health Commission Capacity Building and Continuing Education;China Clinical Practice Guidelines Alliance Methodology Committee;National Children′s Medical Center(Shanghai);National Medical Center for Infectious Diseases;Zeng Mei;Shao Zhujun;Zhang Wenhong;Xia Jun(不详;Department of Infectious Disease,Children′s Hospital of Fudan University,National Children′s Medical Center(Shanghai),Shanghai 200032,China;Institute for Communicable Disease Prevention and Control,Chinese Center for Disease Control and Prevention,Beijing 102206,China;Department of Infectious Diseases,Huashan Hospital,Fudan University,National Medical Center for Infectious Diseases,Shanghai 200040,China;GRADE Centre,Uniersity of Nottingham Ningbo,Ningbo 315100,China)

机构地区：[1]不详 [2]复旦大学附属儿科医院感染传染科,国家儿童医学中心(上海),上海200032 [3]中国疾病预防控制中心传染病预防控制所,北京102206 [4]复旦大学附属华山医院感染科,国家传染病医学中心,上海200040 [5]宁波诺丁汉大学GRADE中心,宁波315100 [6]复旦大学附属儿科医院感染传染科 [7]复旦大学附属闵行医院检验科 [8]上海临床研究中心儿科 [9]首都医科大学附属北京儿童医院北京市儿科研究所感染与微生物研究室,国家儿童医学中心(北京)

出　　处：《中华医学杂志》2024年第15期1258-1279,共22页National Medical Journal of China

基　　金：上海市第六轮加强公共卫生建设三年行动计划(GWVI-2.1.2)

摘　　要：百日咳再现是全球性的公共卫生问题,2018—2022年我国国内百日咳报告发病率接近20世纪80年代末的报告水平。实际上,我国的百日咳发病率被严重低估,主要因为国内尚未全面建立百日咳主动监测工作,不典型百日咳病例在临床上容易被漏诊,许多医疗机构未开展百日咳的实验室诊断;同时,我国还面临百日咳鲍特菌对一线抗菌药物大环内酯类高度耐药的临床问题。为了更好地指导和规范我国百日咳病例的临床诊疗、监测和防控工作,由感染病学、流行病学、免疫规划及指南方法学专家组成指南制订小组,从实践角度提出有关百日咳诊断、治疗、预防,尤其是疫苗免疫策略的12个临床问题,经过研究问题构建、证据检索和综合、证据评价以及证据到推荐意见讨论,制订推荐意见和实施建议,为从事百日咳诊疗和防控的临床医师、微生物实验室专业人员、医院感染控制专业人员以及公共卫生领域从事传染病防控和免疫规划的专业人员提供参考。Pertussis re-emergence is a global public health concern.The reported incidence of pertussis in China from 2018 to 2022 was comparable to that in the late 1980s.In fact,the incidence of pertussis is still significantly underestimated in China,owing to a lack of comprehensive active pertussis surveillance,missed diagnosis of atypical pertussis cases,and the fact that many medical institutions do not perform pertussis laboratory diagnosis.Meanwhile,China is also faced with the clinical issue that Bordetella pertussis is highly resistant to first-line macrolide treatment.To better guide and standardize the clinical diagnosis,treatment,monitoring,prevention and control of pertussis cases in China,a multidisciplinary guideline development group comprised of experts in infectious diseases,epidemiology,immunization planning and guideline methodology proposed 12 clinical issues related to the diagnosis,treatment and prevention,especially vaccine immunization strategies from a practical perspective.Through research question construction,evidence retrieval and synthesis,evidence appraisal and evidence-to-decision discussion,recommendations and implementation suggestions were formulated to provide references for clinical physicians engaged in the diagnosis and management of pertussis,microbiological laboratory professionals,hospital infection control professionals,and public health professionals involved in infectious disease prevention,control and immunization planning.

关 键 词：百日咳 诊断 治疗 预防 疫苗接种 

分 类 号：R516.6[医药卫生—内科学]